Hepatotoxicity due to lysine salt of bendazac.
BACKGROUND
The lysine salt of bendazac is a non-steroidal anti-inflammatory agent, and it is marketed exclusively for the treatment of cataracts. We report two cases of possible hepatotoxicity due to the use of bendazac lysine.


METHODS
Laboratory tests, serologic tests, abdominal sonography and scan were performed to study liver disease.


RESULTS
Reversible increases of the hepatic enzymes were found in both cases. Anemia was also found in one of the cases (case 1).


CONCLUSIONS
Abnormal liver test results could be related to a possible liver injury attributed to the use of bendazac lysine.
Alcalde
M
M
Gastroenterology Dept. Infanta Cristina University Hospital, University of Extremadura, Badajoz, Spain.
Garcia-Diaz
M
M
Najarro
F
F
Donoso
M S
MS
Cebria
L
L
Pascasio
J M
JM
D000368:Aged; D000369:Aged, 80 and over; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects* / Q000627:therapeutic use; D002386:Cataract / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D007191:Indazoles / Q000009:adverse effects* / Q000627:therapeutic use; D008111:Liver Function Tests
D000894:Anti-Inflammatory Agents, Non-Steroidal; D007191:Indazoles; C036067:bendazac lysine